Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Measuring Omalizumab Responses Using Real-world Evidence (MORRE) Study

NCT04724278 is registered in ClinicalTrials.gov with National Jewish Health as lead sponsor.

NCT NCT04724278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04724278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Measuring Omalizumab Responses Using Real-world Evidence (MORRE) Study
Lead sponsor
National Jewish Health
Phase
Observational
Overall status
Unknown status
Start date
February 5, 2021
Completion date
July 15, 2023
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma